- organizations:Harrow
Products
Harrow launches VEVYE accessibility program for patients
VEVYE Access for All initiative eliminates prior authorization submission delays, expedites prescription deliveries, and lowers prescription costs for qualifying patients.
Research
Harrow reports 52-week data from phase 3 VEVYE extension study
FDA-approved cyclosporine solution to treat DED sustains statistically significant improvements in safety and efficacy, with continuous tear production improvements.
Products
VEVYE is officially available in the US
Prescription-based cyclosporine formulation is indicated to treat the signs and symptoms of dry eye disease.
Products
Harrow prepares to launch widespread market access for VEVYE
Company is partnering with three major healthcare tech platforms ahead of product launch next week.
Products
Harrow purchases US, Canadian commercial rights to Novaliq's VEVYE
Newly-FDA-approved product is the first and only cyclosporine water- and preservative-free solution indicated for DED treatment.
Business
Harrow partners with Asembia for expanded branded ophthalmic product access
Partnership aims to simplify the prescribing process and ensure accessibility and affordability for patients; company also reports new Medicare coverage for VEVYE.
Products